Enhertu 100mg Injection

• Stomach cancer
• Metastatic breast cancer  

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Enhertu 100mg Injection also causes some adverse impact on the body, most of which resolve without any medical attention. Some common side effects include:

• Nausea
• Fever
• Fatigue
• Vomiting
• Hair loss
• Constipation
• Diarrhea
• Decreased appetite
• Musculoskeletal (bone, muscle or joint) pain
• Abdominal pain
• Decreased white blood cell count
• Decreased hemoglobin
• Decreased white blood cell count (neutrophils)
• Decreased white blood cell count (lymphocytes)
• Low blood platelets
• Increased aspartate aminotransferase
• Increased alanine aminotransferase
• Increased alkaline phosphatase level in blood
• Decreased potassium level in blood
• Increased bilirubin in the blood

Seek medical attention in case of any unusual or severe side effects immediately

• Enhertu 100mg is available in injection form and is advised to be taken as per the doctor's prescription. It should be administered by a doctor or experienced nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  

• Enhertu 100mg Injection is an anticancer medicine with active ingredient Trastuzumab Deruxtecan. It is a targeted anticancer that detects HER2 protein-rich cancer cells.
• It works by detecting and attaching to those cancer cells consisting of specific proteins cancer cells to inhibit their growth & multiplication.
• This injection directly damages and destroys the cancer cell without harming surrounding healthy cells.

• Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., ... & Cameron, D. A. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387(1), 9-20. https://pubmed.ncbi.nlm.nih.gov/35665782/
• Hurvitz, S. A., Hegg, R., Chung, W. P., Im, S. A., Jacot, W., Ganju, V., ... & Cortés, J. (2023). Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet, 401(10371), 105-117. https://pubmed.ncbi.nlm.nih.gov/38796287/
• Andrikopoulou, A., Zografos, E., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2021). Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer. Clinical breast cancer, 21(3), e212-e219. https://pubmed.ncbi.nlm.nih.gov/32917537/
• Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S. B., Tamura, K., ... & Krop, I. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New England Journal of Medicine, 382(7), 610-621. https://www.nejm.org/doi/full/10.1056/NEJMoa1914510
• Cortés, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., ... & Hurvitz, S. A. (2022). Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. New England Journal of Medicine, 386(12), 1143-1154. https://pubmed.ncbi.nlm.nih.gov/31825192/